The Dales Report

We begin with Pelorus Equity Group President Rob Sechrist who shares why mergers and acquisition will not happen this year in the Cannabis industry, and why the public equity market will remain volatile.Rob also outlines how his firm built out a data proprietary tool where they were the first to know where every license Cannabis operator in the country was located, who owned them, what type of licenses, where they’re physically situated, who owns the real estate, the price per pound in that region, the power costs, and 2 years of data points where they can now look for trends.By achieving all of this, it has enabled them to grow their lending assets by more than 50% in the past year to almost $400,000,000. Their goal for 2023 is to grow to over $1,000,000,000 in lending assets, which then provides 15% annual returns within their equity fund which also includes monthly distributions.

atai Life Sciences Founder Christian Angermayer explains that all will be fine long term for atai Life Sciences, and that the latest news concerning less than favorable clinical results is part of the research process in biotech.In addition, Angermayer explains that out of all of the companies he’s invested in, he feels most confident with atai Life Sciences. Reason why is because of the hefty war chest they have for research, and also the current mental health landscape that is affecting people across the world.

We begin our latest Trade to Black podcast by making the most significant stock market predictions in 2023, what impact new Speaker of The House Kevin McCarthy will have on the economy, and why federal cannabis legalization is dead for 2023.In addition, we explain why you should blame people like Michael Saylor for the FTX fiasco and not Kevin O’Leary and why Ethereum might be an attractive buy at the current price.